A highly immunogenic fragment derived from Zaire Ebola virus glycoprotein elicits effective neutralizing antibody

Virus Research

Volumn 189, Issue , 2014, Pages 254-261

  Wang, Yu ^a   Liu, Zhuguo ^a   Dai, Qiuyun ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

Fragment; Glycoprotein; Immunogenicity; Neutralizing antibody; Polyvalent vaccine; Zaire ebola virus

Indexed keywords

EBOLA VACCINE; FREUND ADJUVANT; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 2; MEMBRANE PROTEIN; MONOMER; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; SIGNAL PEPTIDE; VIRUS GLYCOPROTEIN; VIRUS VACCINE; CYTOKINE; DNA VACCINE; ENVELOPE GLYCOPROTEIN, EBOLA VIRUS; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DEMOCRATIC REPUBLIC CONGO; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; RECOMBINANT PLASMID; SPLEEN CELL; SUDAN; T LYMPHOCYTE; VACCINE PRODUCTION; VESICULAR STOMATITIS VIRUS; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL PROLIFERATION; EPITOPE MAPPING; GENETICS; IMMUNOLOGY; MONONUCLEAR CELL; PROTEIN TERTIARY STRUCTURE; SECRETION (PROCESS); SPLEEN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL PROLIFERATION; CYTOKINES; EBOLA VACCINES; EBOLAVIRUS; EPITOPE MAPPING; FEMALE; LEUKOCYTES, MONONUCLEAR; MICE, INBRED BALB C; PROTEIN STRUCTURE, TERTIARY; SPLEEN; VACCINES, DNA; VIRAL ENVELOPE PROTEINS;

EID: 84905967667     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.06.001     Document Type: Article

References (38)

1. Beer B., Kurth R., Bukreyev A. Characteristics of Filoviridae: Marburg and Ebola viruses. Naturwissenschaften 1999, 86(1):8-17.
2. Berlec A., Malovrh T., Zadravec P., Steyer A., Ravnikar M., Sabotič J., Poljšak-Prijatelj M., Štrukelj B. Expression of a hepatitis A virus antigen in Lactococcus lactis and Esherichia coli and evaluation of its immunogenicity. Appl. Microbiol. Biotechnol. 2013, 97(10):4333-4342.
3. Carey B.W., Markoulaki S., Hanna J., Saha K., Gao Q., Mitalipova M., Jaenisch R. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(1):157-162.
4. Chan S.Y., Ma M.C., Goldsmith M.A. Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J. Gen. Virol. 2000, 81(9):2155-2159.
5. Dowling W., Thompson E., Badger C., Mellquist J.L., Garrison A.R., Smith J.M., Paragas J., Hogan R.J., Schmaljohn C. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. J. Virol. 2007, 81(4):1821-1837.
6. Elliott L.H., Kiley M.P., McCormick J.B. Descriptive analysis of Ebola virus proteins. Virology 1985, 147(1):169-176.
7. Feldmann H., Geisbert T. Ebola haemorrhagic fever. Lancet 2011, 277(9768):849-862.
8. Feldmann H., Jones S.M., Daddario-DiCaprio K.M., Geisbert J.B., Ströher U., Grolla A., Bray M., Fritz E.A., Fernando L., Feldmann F., Hensley L.E., Geisbert T.W. Effective postexposure treatment of Ebola infection. PLoS Pathog. 2007, 3(1):e2.
9. Francica J.R., Matukonis M.K., Bates P. Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein. Virology 2009, 383(2):237-247.
10. Garbutt M., Liebscher R., Wahl-Jensen V., Jones S., Möller P., Wagner R., Volchkov V., Klenk H.D., Feldmann H., Ströher U. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 2004, 78(10):5458-5465.
11. Geisbert T.W., Daddario-DiCaprio K.M., Lewis M.G., Geisbert J.B., Grolla A., Leung A., Paragas J., Matthias L., Smith M.A., Jones S.M., Hensley L.E., Feldmann H., Jahrling P.B. Vesicular stomatitis virus-based Ebola vaccines is well-tolerated and protects immunocompromised nohuman primates. PLoS Pathog. 2008, 4(11):e1000225.
12. Geisbert T.W., Geisbert J.B., Leung A., Daddario-DiCaprio K.M., Hensley L.E., Grolla A., Feldmann H. Single-injection vaccine protects nohuman primates against infection with Marburg virus and three species of Ebola virus. J. Virol. 2009, 83(14):7296-7304.
13. Gene O.G., Julia B.E., Melanson R., Vanessa M.R., Victoria W.-J., Thomas G.W., Lisa H.E. Drug targets in infections with Ebola and Marburg viruses. Infect. Disord. Drug Targets 2009, 9(2):191-200.
14. Haglund K., Forman J., Kräusslich H.G., Rose J.K. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 2000, 268(1):1120121.
15. Hensley L.E., Mulangu S., Asiedu C., Johnson J., Honko A.N., Daphne Stanley, Fabozzi G., Nichol S.T., Ksiazek T.G., Rollin P.E., Wahl-Jensen V., Bailey M., Jahrling P.B., Roederer M., Koup R.A., Sullivan N.J. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog. 2010, 6(5):e1000904.
16. Jeffers S.A., Sanders D.A., Sanchez A. Covalent modifications of the ebola virus glycoprotein. J. Virol. 2002, 76(24):12463-12472.
17. Jones S.M., Feldmann H., Ströher U., Geisbert J.B., Fernando L., Grolla A., Klenk H.-D., Sullivan N.J., Volchkov V.E., Fritz E.A., Daddario K.M., Hensley L.E., Jahrling B.P., Geisbert T.W. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 2005, 11(7):786-790.
18. Kuhn J.H., Becker S., Ebihara H., Geisbert T.W., Johnson K.M., Kawaoka Y., Lipkin W.l., Negredo A.I., Netesov S.V., Nicjol S.T., Palacios G., Peters C.L., Volchkov A.E., Jahrling P.B. Proposal for a revised taxonomy of the family filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch. Virol. 2010, 155(12):2083-2103.
19. Kuhn J.H., Becker S., Ebihara H., Geisbert T.W. Family Filoviridae. Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses. 2011, Elsevier/Academic Press, London, UK. A.M.Q. King, M.J. Adams, E.B. Carstens, E.J. Lefkowitz (Eds.).
20. Lee J.E., Saphire E.O. Ebola virus glycoprotein structure and mechanism of entry. Future Virol. 2009, 4(6):621-635.
21. Lee J.E., Kuehne A., Abelson D.M., Fusco M.L., Hart M.K., Saphire E.O. Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a Vλx light chain. J. Mol. Biol. 2008, 375(1):202-216.
22. Lee J.E., Fusco M.L., Hessell A.J., Oswald W.B., Burton D.R., Saphire E.O. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008, 484(7201):177-182.
23. Marzi A., Engelmann F., Feldmann F., Haberthur K., Shupert W.L., Brining D., Scott D.P., Geisbert T.W., Kawaoka Y., Katze M.G., Feldmann H., Messaoudi I. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl. Acad. Sci. U.S.A. 2013, 110(5):1893-1898.
24. Mire C.E., Miller A.D., Carville A., Westmoreland S.V., Geisbert J.B., Mansfield K.G., Feldmann H., Hensley L.E., Geisbert T.W. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl. Trop. Dis. 2012, 6(3):e1567.
25. Peterson A.T., Bauer J.T., Mills J.N. Ecologic and geographic distribution of filovirus disease. Emerg. Infect. Dis. 2004, 10(1):40-47.
26. Petrushina I., Tran M., Sadzikava N., Ghochikyan A., Vasilevko V., Agadjanyan M.G., Cribbs D.H. Importance of IgG2c isotype in the immune response to b-amyloid in amyloid precursor protein/transgenic mice. Neurosci. Lett. 2003, 338(1):5-8.
27. Qiu Xiangguo, Alimonti J.B., Melito P.L., Fernando L., Ströher U., Jones S.M. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin. Immunol. 2011, 141(2):218-227.
28. Richardson J.S., Yao M.K., Tran K.N., Croyle M.A., Strong J.E., Feldmann H., Kobinger G.P. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009, 4(4):e5308.
29. Simmons G., Wool-Lewis R.J., Baribaud F., Netter R.C., Bates P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 2002, 76(5):2518-2528.
30. Sullivan N.J., Peterson M., Yang Z.-y., Kong W.-p., Duckers H., Nabel E., Nabel G.J. Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J. Virol. 2005, 79(1):547-553.
31. Suo S., Ren Y., Li G., Zarlenga D., Bu R.E., Su D., Li X., Li P., Meng F., Wang C., Ren X. Immune responses induced by DNA vaccines bearing Spike gene of PEDV combined with porcine IL-18. Virus Res. 2012, 167(2):259-266.
32. Takada A., Feldmann H., Stroeher U., Bray M., Watanabe S., Ito H., McGregor M., Kawaoka Y. Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J. Virol. 2003, 77(2):1069-1074.
33. Tang W., Ehrlich I., Wolff S.B., Michalski A.M., Wölfl S., Hasan M.T., Lüthi A., Sprengel R. Faithful expression of multiple proteins via 2A-peptide self-processing: a versatile and reliable method for manipulating brain circuits. J. Neurosci. 2009, 29(27):8621-8629.
34. Volchkov V.E., Feldmann H., Volchkova V.A., Klenk H.D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(10):5762-5767.
35. Whitt M.A. Generation of VSV pseudotypes using recombinant δG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 2010, 169(2):365-374.
36. Wilson J.A., Hevey M., Guest S., Bray M., Schmaljohn A.L., Hart M.K. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000, 287(5458):1664-1666.
37. Yang Z.Y., Duckers H.J., Sullivan N.J., Sanchez A., Nabel E.G., Nabel G.J. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 2000, 6(8):886-889.
38. Zhang Jianhua, Dong Min, Jiang Bingfu, Dai Xing, Meng Jihong Antigenic characteristics of the complete and truncated capsid protein VP1 of enterovirus 71. Virus Res. 2012, 167(2):337-342.